Last reviewed · How we verify

HX008

Taizhou Hanzhong biomedical co. LTD · Phase 3 active Small molecule

HX008 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 to enhance anti-tumor immune responses.

HX008 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).

At a glance

Generic nameHX008
SponsorTaizhou Hanzhong biomedical co. LTD
Drug classPD-L1 inhibitor
TargetPD-L1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

HX008 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the inhibitory PD-L1/PD-1 axis that tumors exploit to evade immune surveillance. By preventing this interaction, the drug restores T-cell activation and proliferation, enabling the immune system to recognize and eliminate cancer cells. This mechanism is characteristic of immune checkpoint inhibitors used across multiple cancer types.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results